top of page
Modern Office View

Strategic Scientific Advisory & Fractional Leadership

 

Translational strategy for biotech, investors, and innovation teams building human-relevant evidence.

 

NAMina Bio offers founder-led scientific advisory services for early-stage biotech companies, investors, technology developers, and translational research teams seeking rigorous evaluation of preclinical strategy, advanced model systems, and data-driven development plans.

 

Our advisory work is designed to help organizations assess scientific risk, strengthen translational positioning, and build more credible paths from discovery-stage biology to decision-ready evidence.

Bridging Scientific Depth and Strategic Execution

 

The gap between promising early-stage discovery and clinically relevant evidence is one of the most critical risk points in biotechnology.

 

Evaluating a new asset, platform, or translational workflow requires more than a conventional review of a pitch deck or publication package. It requires an understanding of disease biology, preclinical model limitations, human-relevant systems, data quality, regulatory direction, and commercial readiness.

 

Led by Dr. Paola Dama, PhD, Founder & CEO of NAMina Bio, this advisory service brings together over 15 years of international experience in molecular oncology, immunotherapy, gene therapy, 3D tumor models, organoids, New Approach Methodologies, and biotech business development.

Founder-Led Expertise

 

Dr. Paola Dama brings a rare combination of academic, industry, and entrepreneurial experience across oncology, gene therapy, immunotherapy, and advanced preclinical modeling.

 

Selected credentials include:

 

  • Founder & CEO, NAMina Bio Corp

  • BioLabs@NYU Langone resident startup footprint, New York

  • Former Senior Scientific Product & Business Development Manager, VectorBuilder

  • Visiting Research Fellow, University of Sussex

  • Editorial Board Member, Cancer Gene Therapy

  • Reviewer for leading oncology and translational journals

  • Recipient of Cancer Gene Therapy Reader’s Choice recognition in 2022 and 2024

  • Experience across pharma-sponsored immuno-oncology research, CRISPR functional genomics, viral vectors, 3D tumor biology, and translational oncology

 

 

Engagement Formats

 

Advisory engagements can be structured based on the level of support required.

 

Examples include:

 

  • One-hour strategic consultation

  • Scientific due-diligence review

  • Investor or partner-readiness audit

  • Fractional scientific leadership

  • White paper or technical narrative development

  • Custom advisory mandate for biotech, pharma, or investment teams

 

All engagements are scoped individually based on objectives, timeline, confidentiality requirements, and deliverables.

​
 

​

Fractional Scientific Leadership

Senior biotech expertise for strategic growth and technical positioning.

1 hLocation 1

Service Description

Expert senior-level guidance for biotech startups focusing on translational roadmaps, preclinical study design, and NAM-integrated strategies. This service bridges the gap for early-stage teams needing high-level strategic support without the overhead for a full-time executive. Services may include: Translational roadmap development Preclinical study design and model-selection strategy 3D tumor model, organoid, NAM, and organ-on-chip advisory Scientific narrative refinement for fundraising, grants, and partnerships Support for technical positioning, advisory decks, and investor-facing materials

Contact Details

  • 500 Terry Francine Street, 6th Floor, San Francisco, CA 94158

    123-456-7890

    info@mysite.com

bottom of page